Comparative Assessment of the Long-Term Effectiveness and Safety of Dapagliflozin and Empagliflozin as Add-on Therapy to Hypoglycemic Drugs in Patients with Type 2 Diabetes

Table 3

Relationship between the ΔHbA1c and the clinical parameters at baseline.

	ΔHbA1c (univariate)		ΔHbA1c (multivariate)
	r
Gender, female	0.063	0.177
Age, years	0.117	0.011	0.903	0.367
Body weight	-0.101	0.030	-1.495	0.136
Systolic blood pressure	0.053	0.252
Diastolic blood pressure	0.036	0.440
Baseline FPG	-0.307	<0.001	-0.111	0.912
Baseline HbA1c	-0.482	<0.001	-12.46	<0.001
Baseline eGFR	-0.092	0.047	-0.875	0.382
Hypertension	0.042	0.363
Dyslipidemia	0.004	0.937
History of stroke/TIA	-0.059	0.201
CAD (MI, IHD)	0.082	0.075
Heart failure	-0.004	0.927
Heart arrhythmia	-0.019	0.686
Metformin	0.104	0.024	0.840	0.401
Sulfonylurea	-0.001	0.981
Pioglitazone	0.003	0.944
DDP-4 inhibitor	0.010	0.830
Acarbose	0.017	0.722
Insulin	-0.035	0.447
GLP-1 agonist	0.089	0.053

CAD: coronary artery disease; DDP-4: dipeptidyl peptidase-4; eGFR: estimated glomerular filtration rate; FPG: fasting plasma glucose; GLP-1: glucagon-like peptide-1; HbA1c: hemoglobin A1c; IHD: ischemic heart disease; MI: myocardial infarction; TIA: transient ischemic attack. value <0.05 were considered statistically significant ( upper index).